Cardionogen 1
Based on 1 publication(s) in Google Scholar
Cardionogen 1 (CDNG1/vuc230) is a Wnt signaling pathway inhibitor that slows down Myc-induced liver tumorigenesis. Cardionogen 1 treatment of zebrafish embryos before gastrulation inhibits cardiomyocyte formation, whereas treatment during or after gastrulation induces cardiomyocyte formation. Cardionogen 1 has potential in research into cancer and cardiovascular disease.
For research use only. We do not sell to patients.
- Purity : 99.21%
- CAS No.: 577696-37-8
- Formula: C13H14N4OS
- Molecular Weight:274.34
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-12238
IWR-1Wnt Signaling Inhibitor -
HY-13912
IWP-2Wnt Production Inhibitor -
HY-12681
CCT251545WNT Pathway Inhibitor -
HY-15659
Wnt-C59PORCN Inhibitor -
HY-108442
JW67Wnt Signaling Inhibitor -
HY-16665
iCRT 14Wnt Inhibitor -
HY-115539
WindorphenWnt/β-catenin Inhibitor -
HY-15721
FH535Wnt/β-catenin/PPAR Inhibitor -
HY-12879
IWP-4Wnt/CK1δ/ε Inhibitor -
HY-19987
BML-284Wnt Signaling Activator -
HY-101130
PNU-74654β-catenin/TCF Interaction Inhibitor -
HY-122816
HLY78Wnt/β-catenin Activator
Publications Citing Use of MedChemExpress (MCE) Cardionogen 1
More
Biological Activity
Description
Chemical Information
-
CAS No. 577696-37-8
-
Appearance Solid
-
Molecular Weight 274.34
-
Formula C13H14N4OS
-
Color White to off-white
-
SMILES
C12=NN=C(C3=CC=CO3)N1N=C(C4CCCCC4)S2
-
Synonyms
CDNG1/vuc230
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
Protocols
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Yan C, et al. Chemical inhibition reveals differential requirements of signaling pathways in krasV12- and Myc-induced liver tumors in transgenic zebrafish. Sci Rep. 2017 Apr 5;7:45796. [Content Brief]
[2]. Plowright AT, et al. Heart regeneration: opportunities and challenges for drug discovery with novel chemical and therapeutic methods or agents. Angew Chem Int Ed Engl. 2014 Apr 14;53(16):4056-75. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Cardionogen 1 Related Classifications
HY-W011616 Related Classifications
Powered by Bioz